Since its foundation in 1986, PharmaMar has been pursuing a unique approach to the search for new treatments for cancer, by tapping into the reaches of the worldÇs oceans. The companyÍs model is harnessing natureÇs evolution in the enormous biodiversity found in the depths of the sea to discover new cancer targets. The biophysiology of marine organisms hints at the remarkable potential of the marine ecosystem as a source of new compounds that have powerful anticancer properties. Although these molecules are often very complex, PharmaMar is able to transform them into first-in-class therapies; providing new therapies to tackle cancer. Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS¬ in Europe and has other three clinical-stage programs under development for several types of solid and hematological cancers, Lurbinectedin, Apllidin¬, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel.